Shahar Rosenstock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shahar Rosenstock has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Adva Viessman
Gray Faculty of Health Sciences and Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
1 shared publication - Avia Shealtiel
Education Authority, Sheba Medical Center, Tel HaShomer, Ramat Gan 5262100, Israel
1 shared publication - Daniela Belenki Pardilov
Medical University of Silesia, 40-055 Katowice, Poland
1 shared publication - Dmitry Iskilov
ORT Milton School, Bat Yam 5959020, Israel
1 shared publication - Gabriela Kapranov
School of Medicine, University of Nicosia, Nicosia 2417, Cyprus
1 shared publication - Gad Segal
Gray Faculty of Health Sciences and Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Clinics and Practice
- Vol. 16 (11) , 210
High Serum Immunoglobulin G Levels Are Associated with Hypoalbuminemia and Prolonged Coagulation Time in Patients with Autoimmune Hepatitis: A Retrospective Cohort Study
Background: Serum immunoglobulin G (IgG) levels are central to the diagnosis and monitoring of autoimmune hepatitis (AIH), yet the clinical implications of markedly elevated IgG remain incompletely characterized. We examined whether higher maximal serum IgG levels are associated with a biochemical phenotype of more severe hepatic injury, impaired hepatic synthetic function, and adverse clinical outcomes in patients with AIH. Methods: We conducted a retrospective cohort study of 80 adults with AIH treated at Sheba Medical Center. Patients were categorized into low, intermediate, and high IgG strata according to tertiles of maximal documented serum IgG. Demographic characteristics, comorbidities, treatments, admission laboratory values, hepatic synthetic function markers, and mortality outcomes were compared across strata. Primary outcomes were serum albumin, international normalized ratio (INR), hypoalbuminemia and the INR-to-albumin ratio. Secondary outcomes included hepatocellular and cholestatic pathophysiology surrogate markers, hospital length of stay, all-cause mortality during follow-up, and one- and five-year mortality. Results: Among 80 patients, maximal IgG differed significantly across strata (overall median, 2030 [IQR, 1545–2802.5]; low, 1320 [1105–1520]; intermediate, 2040 [1845–2215]; and high, 3310 [2827.5–3747.5]; p < 0.001). Compared with the low-IgG group, the high-IgG group had more frequent hypoalbuminemia (53.8% vs. 11.1%; p = 0.002), more frequent elevated INR values (34.6% vs. 7.4%; p = 0.035), and a higher INR-to-albumin ratio (median, 0.45 vs. 0.30; p < 0.001). Mortality did not differ significantly across IgG strata, including all-cause mortality during follow-up (15.4%, 14.8%, and 14.8%; p = 1.00), one-year mortality (p = 0.49), and five-year mortality (p = 0.72). After adjustment for age, recorded cirrhosis, ALT and corticosteroid exposure, each 1000 mg/dL increase in maximal IgG was associated with 0.248 g/dL lower albumin, 9.5% higher INR and an 18.5% higher INR-to-albumin ratio (all p < 0.001). Conclusions: Higher serum IgG levels in AIH patients were associated with impaired hepatic synthetic function, reflected by lower albumin, higher INR, and a higher INR-to-albumin ratio, without a corresponding increase in short- or intermediate-term mortality in this cohort. Markedly elevated IgG may help identify patients who warrant closer assessment of their synthetic hepatic reserve.
- 9 November 2026
- Published by MDPI AG in Clinics and Practice
- Vol. 16 (11) , 210
Open AccessHigh Serum Immunoglobulin G Levels Are Associated with Hypoalbuminemia and Prolonged Coagulation Time in Patients with Autoimmune Hepatitis: A Retrospective Cohort Study
Background: Serum immunoglobulin G (IgG) levels are central to the diagnosis and monitoring of autoimmune hepatitis (AIH), yet the clinical implications of markedly elevated IgG remain incompletely characterized. We examined whether higher maximal serum IgG levels are associated with a biochemical phenotype of more severe hepatic injury, impaired hepatic synthetic function, and adverse clinical outcomes in patients with AIH. Methods: We conducted a retrospective cohort study of 80 adults with AIH treated at Sheba Medical Center. Patients were categorized into low, intermediate, and high IgG strata according to tertiles of maximal documented serum IgG. Demographic characteristics, comorbidities, treatments, admission laboratory values, hepatic synthetic function markers, and mortality outcomes were compared across strata. Primary outcomes were serum albumin, international normalized ratio (INR), hypoalbuminemia and the INR-to-albumin ratio. Secondary outcomes included hepatocellular and cholestatic pathophysiology surrogate markers, hospital length of stay, all-cause mortality during follow-up, and one- and five-year mortality. Results: Among 80 patients, maximal IgG differed significantly across strata (overall median, 2030 [IQR, 1545–2802.5]; low, 1320 [1105–1520]; intermediate, 2040 [1845–2215]; and high, 3310 [2827.5–3747.5]; p < 0.001). Compared with the low-IgG group, the high-IgG group had more frequent hypoalbuminemia (53.8% vs. 11.1%; p = 0.002), more frequent elevated INR values (34.6% vs. 7.4%; p = 0.035), and a higher INR-to-albumin ratio (median, 0.45 vs. 0.30; p < 0.001). Mortality did not differ significantly across IgG strata, including all-cause mortality during follow-up (15.4%, 14.8%, and 14.8%; p = 1.00), one-year mortality (p = 0.49), and five-year mortality (p = 0.72). After adjustment for age, recorded cirrhosis, ALT and corticosteroid exposure, each 1000 mg/dL increase in maximal IgG was associated with 0.248 g/dL lower albumin, 9.5% higher INR and an 18.5% higher INR-to-albumin ratio (all p < 0.001). Conclusions: Higher serum IgG levels in AIH patients were associated with impaired hepatic synthetic function, reflected by lower albumin, higher INR, and a higher INR-to-albumin ratio, without a corresponding increase in short- or intermediate-term mortality in this cohort. Markedly elevated IgG may help identify patients who warrant closer assessment of their synthetic hepatic reserve.